JCC: The use of metformin reduces the risk of inflammatory bowel disease in patients with type 2 diabetes.

Background and target inflammatory bowel disease (inflammatory bowel disease, IBD) is a class of diseases caused by a variety of etiology, abnormally immune-mediated chronic inflammation of the intestine and intestinal epithelial damage. Autoimmune and intestinal mucosa barriers play an important role in their pathogenesis. The study found that, in addition to the anti-sugar effect, metformin can play an anti-inflammatory role and improve the intestinal mucosa barrier through a variety of mechanisms to regulate the immune response of the intestinal mucosa, so the study aims to compare the risk of inflammatory bowel disease (IBD) between users of metformin and never-before-used.
method researchers collected patients newly diagnosed with type 2 diabetes between 1999 and 2005, and as of January 1, 2006, 340,211 users who had used IBD and 24,478 users who had never used IT were followed up.
the risk ratio was estimated by Cox regression and the treatment weighting was used in combination with the tendentious score.
results 6,466 patients were diagnosed with new disease IBD, and the risk ratio of IBD in patients who had used metformin was 0.55 (95% confidence interval: 0.51-0.60).
the dose-reaction pattern was observed when the cumulative duration of metformin therapy was compared with that of no user.
the first (26.0 months), the second (26.0-58.3 months) and the third (58.3 months), respectively, the risk ratio is 1.00 (0.93-1.09), 0.57 (0.52-0.62) and 0.24 (0.22-0.26).
concluded that the risk of IBD was significantly reduced in patients with type 2 diabetes who received metformin.
.